Tonix Pharmaceuticals Holding Corp. Healthcare | Drug Manufacturers - Major | USA Tonix Pharmaceuticals Holding Corp. engages in developing medicines for common disorders of the central nervous system. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. The company's lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of fibromyalgia; and Phase II clinical stage for the treatment of post-traumatic stress disorder. It also engages in developing TNX-301, a fixed dose combination drug product that contains disulfiram and selegiline for the treatment of alcohol use disorders, as well as biodefense development programs for protection from smallpox virus and radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is headquartered in New York, New York.
Humongous volume today, after releasing Phase II results for their PTSD drug, TNX-102 SL. (This drug is also in Phase III for fibromyalgia). Stock price has gone as low as 1.85 recently. Company has $1.45/share in cash. That translates to ~$25M cash...perhaps the fear is that they will have to raise more cash to fund further testing. http://247wallst.com/healthcare-bus...d-this-be-the-turning-point-for-tonix-pharma/
for info Tonix Pharma (TNXP) Issues Positive Update from End-of-Phase 2/Pre-Phase 3 FDA Meeting for TNX-102 SL in PTSD http://www.streetinsider.com/Corpor...+Meeting+for+TNX-102+SL+in+PTSD/11979686.html TNXP) Pre $2.77 +0.33 +13.52% (HOD 2.90) Friday closed 2.44
NEWS $TNXP Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference
